RGNX
NASDAQ · Biotechnology
Regenxbio Inc
$7.88
-0.46 (-5.52%)
Open$8.16
Previous Close$8.34
Day High$8.23
Day Low$7.82
52W High$16.19
52W Low$5.04
Volume—
Avg Volume923.5K
Market Cap441.43M
P/E Ratio—
EPS$-3.46
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+134.5% upside
Current
$7.88
$7.88
Target
$18.48
$18.48
$13.35
$18.48 avg
$24.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 85.50M | 152.21M | 81.92M |
| Net Income | -233,014,819 | -373,354,703 | 13.19M |
| Profit Margin | -272.5% | -258.9% | 16.1% |
| EBITDA | -221,859,611 | -375,229,892 | 28.49M |
| Free Cash Flow | — | — | 20.59M |
| Rev Growth | -43.8% | -43.8% | +8.8% |
| Debt/Equity | 0.23 | 0.23 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |